News

Publication ERC work programme 2026 and Starting Grant call 2026 open

Published on | 2 months ago

Programmes ERC

The ERC work programme 2026 has been adopted by the European Commission and published on the ERC website and European Commission Funding and Tender portal. More information in this ERC news article. The ERC Starting Grant 2026 call opened for submissions with call deadline 14 October 2025. The call topic page on the F&T portal displays important notifications related to the call under “topic updates”. Tune in to the webinar on the ERC Work Programme 2026 for newcomers today starting at 15 CEST. A webinar for an advanced target audience is coming in September.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1684 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.